Back to Search
Start Over
Identification and validation of a novel prognostic signature and key genes related to development of anaplastic thyroid carcinoma.
Identification and validation of a novel prognostic signature and key genes related to development of anaplastic thyroid carcinoma.
- Source :
- Discover Oncology; 11/19/2024, Vol. 15 Issue 1, p1-16, 16p
- Publication Year :
- 2024
-
Abstract
- Background: Anaplastic thyroid carcinoma (ATC) is a rare but the most aggressive type of thyroid carcinoma. Nevertheless, limited advances were made to reduce mortality and improve survival over the last decades. Therefore, identifying novel diagnostic biomarkers and therapeutic targets for ATC patients is still needed. Materials and methods: RNA sequencing data and corresponding clinical features were available from GEO and TCGA databases. We integrated WGCNA and PPI network analysis to identify hub genes associated with ATC development, and RT-qPCR was employed for data verification. Univariate and LASSO Cox regression analyses were used to generate prognostic signatures. Results: Based on PPI and WGCNA, 6 hub genes were identified, namely KIF2C, PBK, TOP2A, CDK1, KIF20A, and ASPM, which play vital roles in ATC development. Subsequently, RT-qPCR experiments showed that most of these genes were significantly upregulated in CAL-62 cells compared to Nthy-ori 3–1 cells. Moreover, a prognostic signature featuring GPSM2, FGF5, ASXL3, CYP4B1, CLMP, and DUXAP9 was generated, which was also verified by RT-qPCR results and proved as an independent predictor of poorer prognosis of ATC. Additionally, a nomogram incorporating the risk score and clinicopathological parameters was further constructed for accurate prediction of 1-, 3- and 5-year survival probabilities of ATC. Conclusions: Our study identified 6 key genes critical to ATC development and constructed a prognostic signature. These findings provide reliable biomarkers and a relatively comprehensive tumorigenesis profile of ATC, which may inform future strategies for clinical diagnosis and pharmaceutical design. [ABSTRACT FROM AUTHOR]
- Subjects :
- DISEASE risk factors
RNA sequencing
PROGNOSIS
REGRESSION analysis
DRUG target
Subjects
Details
- Language :
- English
- ISSN :
- 27306011
- Volume :
- 15
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Discover Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 180991234
- Full Text :
- https://doi.org/10.1007/s12672-024-01563-3